November 11th 2024
Following the clearance of an investigational new drug application from the FDA, a phase 1 trial will examine the novel antibody-drug conjugate BL-M17D1 in patients with advanced or metastatic solid tumors.
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Community Oncology Connections™: Controversies and Conversations About HER2-Expressing Breast Cancer… Advances in Management from HER2-Low to Positive Disease
View More
Emerging Treatments and Evolving Paradigms in HER2-Low Breast Cancer
View More
Medical Crossfire®: Improving Survival in HR-Positive HER2 Negative Metastatic Breast Cancer – Advances in Es...
December 12, 2024
Register Now!
Matching the Right Patients to the Right Therapies in TNBC: Case-Based Applications of Immune Checkpoint Inhibitors, PARP Inhibitors, and TROP2-Targeted ADCs
View More
Clinical Vignettes™: The Experts Explain How They Integrate PET Imaging into Metastatic HR+ Breast Cancer Care Settings
View More
Matching the Right Patients to the Right Therapies in TNBC: Case-Based Applications of Immune Checkpoint Inhibitors, PARP Inhibitors, and TROP2-Targeted ADCs
View More
School of Breast Oncology® Live Video Webcast: Clinical Updates from San Antonio
View More
Annual Hawaii Cancer Conference
January 25-26, 2025
Register Now!
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
42nd Annual Miami Breast Cancer Conference®
March 6 - 9, 2025
Register Now!
The Evolving Tool Box in Advanced HR+/HER2– Breast Cancer: What You Need to Know About Next-Generation SERDs, PI3K/AKT, ADCs, CDK4/6 and Beyond…
View More
Next-Generation Endocrine Therapy for ER+/HER2- Breast Cancer: Addressing Unmet Needs and Keys to Optimization in Clinical Practice
View More
Empowering Breast Cancer Patients with Non-Opioid Pain Management Innovations
View More
Identifying Health Care Inequities in Screening, Diagnosis, and Trial Access for Breast Cancer Care: Taking Action With Evidence-Based Solutions
View More
Leveraging Multidisciplinary Teams in an Evolving Treatment Landscape for Early- Stage HR+, HER2- Breast Cancer
View More
Coffee Talk™: Navigating the Impact of HER2/3, TROP2, and PARP from Early Stage to Advanced Breast Cancer Care
View More
How We Do It™: Defining HER2 Low on Your Pathology Reports to Make Informed Decisions in Breast Cancer Treatment
View More
Community Practice Connection™: Leveraging Multidisciplinary Teams in an Evolving Treatment Landscape for Early- Stage HR+, HER2- Breast Cancer
View More
Clinical Case Vignette Series™: 41st Annual Miami Breast Cancer Conference®
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
24th Annual International Congress on the Future of Breast Cancer® West
July 18-19, 2025
Register Now!
24th Annual International Congress on the Future of Breast Cancer® East
July 11-12, 2025
Register Now!
Differentiating Adverse Events for Antibody-Drug Conjugates Across Solid Tumor Management
View More
Community Practice Connections™: 23rd Annual International Congress on the Future of Breast Cancer West
View More
23rd Annual School of Breast Oncology
November 6-8, 2025
Register Now!
School of Breast Oncology® (SOBO) Slide & Lecture Library
Joyce O’Shaughnessy, MD
View More
Accuracy of PREDICT+ to Determine OS in Early Breast Cancer
July 31st 2021Elisa Agostinetto, MD, discusses the accuracy of PREDICT+, an online tool used to predict mortality in patients with early breast cancer patients and to aid in clinical decision making, to determine the survival of patients enrolled in the phase 3 ALTTO trial of adjuvant lapatinib with or without trastuzumab versus trastuzumab alone in patients with HER2+ early breast cancer.
Watch
Maintained OS Improvement in Patients With HER2+ Breast Cancer Treated With HER2CLIMB Regimen
July 28th 2021In an interview with Targeted Oncology, Guiseppe Curigliano, MD, an associate professor of Medical Oncology at the University of Milano and the head of the Division of Early Drug Development at the European Institute of Oncology, discussed the HER2Climb study and the impact of tucatinib in HER2-positive breast cancer care.
Read More
Tripathy Discusses the Use of HER2-Positive Breast Cancer Agents Across Other Cancer Types
July 22nd 2021Debu Tripathy, MD, discusses the use of tucatinib, capecitabine, and trastuzumab for the treatment of patients with HER2-positive breast cancer and leptomeningeal disease in other HER2-positive cancer types.
Watch
Olaparib Improves Disease–Free Survival in Early HER2-Negative Breast Cancer
July 20th 2021Patients who recived olaparib after a median follow-up of 2.5 years revealed a 42% reduction in invasive disease–free survival, including local and metastatic recurrence of breast cancer, other new cancers, and death due to any cause.
Read More
In an interview with Targeted Oncology, Rachel Wuerstein, MD, discussed the implications of the KAMILLA trial and the benefit of T-DM1. Wuerstein also discussed the data that show TDM1’s potential use for patients with HER2-positive metastatic breast cancer beyond the standard-of-care second-line setting.
Read More
HER2+ Status at Diagnosis in Patients With mBC Shows More Favorable PFS Than HER2-Negative Status
July 12th 2021A prospective analysis demonstrated a trend toward worse prognosis for patients with metastatic breast cancer who were initially HER2 negative and switched to HER2 positive treated with HER2-directed therapies compared with those who were HER2 positive at diagnosis.
Read More
KAMILLA Trial Shows Practice-Changing Safety/Efficacy for HER2+ mBC
June 24th 2021Rachel Wuerstein, MD, discusses the clinical implications of the results of the KAMILLA trial, which evaluates the benefit of trastuzumab emtansine in patients with HER2-positive breast cancer who have received prior anti-HER2 and chemotherapy-based treatment.
Watch
Tucatinib/Capecitabine/Trastuzumab Studied in HER2+ Breast Cancer With LMD
June 17th 2021Debu Tripathy, MD, discusses the TBCRC049 study investigating the use of tucatinib, capecitabine, and trastuzumab in the cerebral spinal fluid of patients with HER2-positive breast cancer and leptomeningeal disease.
Watch
Extended PFS Achieved With [vic-]Trastuzumab Duocarmazine in HER2-Positive Breast Cancer
June 11th 2021Treatment with [vic-]trastuzumab duocarmazine (SYD985) demonstrated a statistically significant improvement in progression-free survival compared with physician’s choice of treatment in patients with pretreated HER2-positive unresectable locally advanced or metastatic breast cancer, meeting the primary end point of the phase 3 TULIP study, according to a press release from Byondis B.V.
Read More
Neoadjuvant Anthracycline-Free Regimen Achieves pCR With Less Toxicity in HER2+ Breast Cancer
June 6th 2021Pertuzumab, trastuzumab, and nab-paclitaxel used as neoadjuvant therapy in patients with HER2-positive locally advanced breast cancer showed comparable pathologic complete response with docetaxel, carboplatin, trastuzumab, and pertuzumab with less toxicities.
Read More
Tucatinib Concentrations Measured in CSF of Patients With HER2+ Metastatic Breast Cancer
June 4th 2021In a pharmacokinetic analysis of the first 15 patients in the phase 2 TBCRC049 study, researchers saw the first evidence for concentrations of tucatinib and ONT-993 in the cerebral spinal fluid of patients with HER2+ metastatic breast cancer with newly diagnosed leptomeningeal metastasis.
Read More
Doctors Debate: Is Neoadjuvant Chemotherapy Appropriate for T1c HR-, HER2+ Breast Cancer?
May 20th 2021A standing question for oncologists is what to do for patients with tumors smaller than 2 cm. The question led to a debate on whether to administer neoadjuvant chemotherapy to patients with T1c hormone receptor–negative, HER2-positive breast cancer during the 38th Annual Miami Breast Cancer Conference.
Read More
Anti-HER2 Treatments Can Cause Pulmonary Toxicities in HER2+ Breast Cancer
May 12th 2021Charles Powell, MD, MBA, discusses the questions surrounding pulmonary toxicities when using anti-HER2 monoclonal antibodies such as trastuzumab deruxtecan for patients with HER2-positive metastatic breast cancer.
Watch